Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2010

Open Access 01-12-2010 | Research

Estrogen receptor α (ERα) mediates 17β-estradiol (E2)-activated expression of HBO1

Authors: Wen-zhong Wang, Hai-ou Liu, Yi-hong Wu, Yi Hong, Jun-wu Yang, Ye-heng Liu, Wei-bin Wu, Lei Zhou, Lin-lin Sun, Jie-jie Xu, Xiao-jing Yun, Jian-xin Gu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Login to get access

Abstract

Background

HBO1 (histone acetyltransferase binding to ORC1) is a histone acetyltransferase (HAT) which could exert oncogenic function in breast cancer. However, the biological role and underlying mechanism of HBO1 in breast cancer remains largely unknown. In the current study, we aimed to investigate the role of HBO1 in breast cancer and uncover the underlying molecular mechanism.

Methods

Immunohistochemistry was applied to detect HBO1 protein expression in breast cancer specimens (n = 112). The expression of protein level was scored by integral optical density (IOD) for further statistical analyses using SPSS. Real-time PCR was used to simultaneously measure mRNA levels of HBO1. The HBO1 protein expression in breast cancer cells was confirmed by western blot.

Results

HBO1 was highly expressed in breast cancer tissues and significantly correlated with estrogen receptor α (ERα) (p < 0.001) and progestational hormone (PR) (p = 0.002). HBO1 protein level also correlated positively with histology grade in ERα positive tumors (p = 0.016) rather than ERα negative tumors. 17β-estradiol (E2) could upregulate HBO1 gene expression which was significantly inhibited by ICI 182,780 or ERα RNAi. E2-increased HBO1 protein expression was significantly suppressed by treatment with inhibitor of MEK1/2 (U0126) in T47 D and MCF-7 cells.

Conclusions

HBO1 was an important downstream molecule of ERα, and ERK1/2 signaling pathway may involved in the expression of HBO1 increased by E2.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRef Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRef
2.
go back to reference Liao DZ, Pantazis CG, Hou X, Li SA: Promotion of estrogen-induced mammary gland carcinogenesis by androgen in the male Noble rat: probable mediation by steroid receptors. Carcinogenesis. 1998, 19: 2173-80. 10.1093/carcin/19.12.2173.CrossRef Liao DZ, Pantazis CG, Hou X, Li SA: Promotion of estrogen-induced mammary gland carcinogenesis by androgen in the male Noble rat: probable mediation by steroid receptors. Carcinogenesis. 1998, 19: 2173-80. 10.1093/carcin/19.12.2173.CrossRef
3.
go back to reference Pettersson K, Gustafsson JA: Role of estrogen receptor beta in estrogen action. Annu Rev Physiol. 2001, 63: 165-92. 10.1146/annurev.physiol.63.1.165.CrossRef Pettersson K, Gustafsson JA: Role of estrogen receptor beta in estrogen action. Annu Rev Physiol. 2001, 63: 165-92. 10.1146/annurev.physiol.63.1.165.CrossRef
4.
go back to reference Hilakivi-Clarke L, Cho E, Cabanes A, et al: Dietary modulation of pregnancy estrogen levels and breast cancer risk among female rat offspring. Clin Cancer Res. 2002, 8: 3601-10. Hilakivi-Clarke L, Cho E, Cabanes A, et al: Dietary modulation of pregnancy estrogen levels and breast cancer risk among female rat offspring. Clin Cancer Res. 2002, 8: 3601-10.
5.
go back to reference Clarke R, Liu MC, Bouker KB, et al: Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003, 22: 7316-39. 10.1038/sj.onc.1206937.CrossRef Clarke R, Liu MC, Bouker KB, et al: Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene. 2003, 22: 7316-39. 10.1038/sj.onc.1206937.CrossRef
6.
go back to reference O'Lone R, Frith MC, Karlsson EK, Hansen U: Genomic targets of nuclear estrogen receptors. Mol Endocrinol. 2004, 18: 1859-75. 10.1210/me.2003-0044.CrossRef O'Lone R, Frith MC, Karlsson EK, Hansen U: Genomic targets of nuclear estrogen receptors. Mol Endocrinol. 2004, 18: 1859-75. 10.1210/me.2003-0044.CrossRef
7.
go back to reference Iizuka M, Takahashi Y, Mizzen CA, et al: Histone acetyltransferase Hbo1: catalytic activity, cellular abundance, and links to primary cancers. Gene. 2009, 436: 108-14. 10.1016/j.gene.2009.01.020.CrossRef Iizuka M, Takahashi Y, Mizzen CA, et al: Histone acetyltransferase Hbo1: catalytic activity, cellular abundance, and links to primary cancers. Gene. 2009, 436: 108-14. 10.1016/j.gene.2009.01.020.CrossRef
8.
go back to reference Hu X, Stern HM, Ge L, et al: Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res. 2009, 7: 511-22. 10.1158/1541-7786.MCR-08-0107.CrossRef Hu X, Stern HM, Ge L, et al: Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res. 2009, 7: 511-22. 10.1158/1541-7786.MCR-08-0107.CrossRef
9.
go back to reference Georgiakaki M, Chabbert-Buffet N, Dasen B, et al: Ligand-controlled interaction of histone acetyltransferase binding to ORC-1 (HBO1) with the N-terminal transactivating domain of progesterone receptor induces steroid receptor coactivator 1-dependent coactivation of transcription. Mol Endocrinol. 2006, 20: 2122-40. 10.1210/me.2005-0149.CrossRef Georgiakaki M, Chabbert-Buffet N, Dasen B, et al: Ligand-controlled interaction of histone acetyltransferase binding to ORC-1 (HBO1) with the N-terminal transactivating domain of progesterone receptor induces steroid receptor coactivator 1-dependent coactivation of transcription. Mol Endocrinol. 2006, 20: 2122-40. 10.1210/me.2005-0149.CrossRef
10.
go back to reference Wang Y, Zong H, Chi Y, et al: Repression of estrogen receptor alpha by CDK11p58 through promoting its ubiquitin-proteasome degradation. J Biochem. 2009, 145: 331-43. 10.1093/jb/mvn177.CrossRef Wang Y, Zong H, Chi Y, et al: Repression of estrogen receptor alpha by CDK11p58 through promoting its ubiquitin-proteasome degradation. J Biochem. 2009, 145: 331-43. 10.1093/jb/mvn177.CrossRef
11.
go back to reference Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987, 8: 138-40. Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987, 8: 138-40.
12.
go back to reference MacGregor JI, Jordan VC: Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 1998, 50: 151-96. MacGregor JI, Jordan VC: Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev. 1998, 50: 151-96.
13.
go back to reference Wakeling AE: Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer. 2000, 7: 17-28. 10.1677/erc.0.0070017.CrossRef Wakeling AE: Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer. 2000, 7: 17-28. 10.1677/erc.0.0070017.CrossRef
14.
go back to reference Clark J, Edwards S, John M, et al: Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. Genes Chromosomes Cancer. 2002, 34: 104-14. 10.1002/gcc.10039.CrossRef Clark J, Edwards S, John M, et al: Identification of amplified and expressed genes in breast cancer by comparative hybridization onto microarrays of randomly selected cDNA clones. Genes Chromosomes Cancer. 2002, 34: 104-14. 10.1002/gcc.10039.CrossRef
15.
go back to reference Hyman E, Kauraniemi P, Hautaniemi S, et al: Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res. 2002, 62: 6240-5. Hyman E, Kauraniemi P, Hautaniemi S, et al: Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res. 2002, 62: 6240-5.
16.
go back to reference Pollack JR, Sorlie T, Perou CM, et al: Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA. 2002, 99: 12963-8. 10.1073/pnas.162471999.CrossRef Pollack JR, Sorlie T, Perou CM, et al: Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA. 2002, 99: 12963-8. 10.1073/pnas.162471999.CrossRef
17.
go back to reference Miotto B, Struhl K: HBO1 histone acetylase is a coactivator of the replication licensing factor Cdt1. Genes Dev. 2008, 22: 2633-8. 10.1101/gad.1674108.CrossRef Miotto B, Struhl K: HBO1 histone acetylase is a coactivator of the replication licensing factor Cdt1. Genes Dev. 2008, 22: 2633-8. 10.1101/gad.1674108.CrossRef
18.
go back to reference Yager JD, Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006, 354: 270-82. 10.1056/NEJMra050776.CrossRef Yager JD, Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006, 354: 270-82. 10.1056/NEJMra050776.CrossRef
19.
go back to reference Stabile LP, Siegfried JM: Estrogen receptor pathways in lung cancer. Curr Oncol Rep. 2004, 6: 259-67. 10.1007/s11912-004-0033-2.CrossRef Stabile LP, Siegfried JM: Estrogen receptor pathways in lung cancer. Curr Oncol Rep. 2004, 6: 259-67. 10.1007/s11912-004-0033-2.CrossRef
20.
go back to reference Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ: Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids. 2007, 72: 135-43. 10.1016/j.steroids.2006.11.019.CrossRef Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ: Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids. 2007, 72: 135-43. 10.1016/j.steroids.2006.11.019.CrossRef
21.
go back to reference Huss JM, Kelly DP: Nuclear receptor signaling and cardiac energetics. Circ Res. 2004, 95: 568-78. 10.1161/01.RES.0000141774.29937.e3.CrossRef Huss JM, Kelly DP: Nuclear receptor signaling and cardiac energetics. Circ Res. 2004, 95: 568-78. 10.1161/01.RES.0000141774.29937.e3.CrossRef
22.
go back to reference Meyer MR, Haas E, Barton M: Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension. 2006, 47: 1019-26. 10.1161/01.HYP.0000223064.62762.0b.CrossRef Meyer MR, Haas E, Barton M: Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension. 2006, 47: 1019-26. 10.1161/01.HYP.0000223064.62762.0b.CrossRef
23.
go back to reference Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB: MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene. 2002, 21: 4000-8. 10.1038/sj.onc.1205506.CrossRef Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB: MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance. Oncogene. 2002, 21: 4000-8. 10.1038/sj.onc.1205506.CrossRef
24.
go back to reference Martin LA, Farmer I, Johnston SR, Ali S, Dowsett M: Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr Relat Cancer. 2005, 12 (Suppl 1): S75-84. 10.1677/erc.1.01023.CrossRef Martin LA, Farmer I, Johnston SR, Ali S, Dowsett M: Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr Relat Cancer. 2005, 12 (Suppl 1): S75-84. 10.1677/erc.1.01023.CrossRef
25.
go back to reference Santen RJ, Song RX, McPherson R, et al: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 2002, 80: 239-56. 10.1016/S0960-0760(01)00189-3.CrossRef Santen RJ, Song RX, McPherson R, et al: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 2002, 80: 239-56. 10.1016/S0960-0760(01)00189-3.CrossRef
26.
go back to reference Migliaccio A, Pagano M, Auricchio F: Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells. Oncogene. 1993, 8: 2183-91. Migliaccio A, Pagano M, Auricchio F: Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells. Oncogene. 1993, 8: 2183-91.
27.
go back to reference Auricchio A, di Domenico M, Castoria G, Bilancio A, Migliaccio A: Epidermal growth factor induces protein tyrosine phosphorylation and association of p190 with ras-GTP-ase activating protein in Caco-2 cells. FEBS Lett. 1994, 353: 16-20. 10.1016/0014-5793(94)00987-2.CrossRef Auricchio A, di Domenico M, Castoria G, Bilancio A, Migliaccio A: Epidermal growth factor induces protein tyrosine phosphorylation and association of p190 with ras-GTP-ase activating protein in Caco-2 cells. FEBS Lett. 1994, 353: 16-20. 10.1016/0014-5793(94)00987-2.CrossRef
28.
go back to reference Auricchio F, Migliaccio A, Castoria G, Di Domenico M, Bilancio A, Rotondi A: Protein tyrosine phosphorylation and estradiol action. Ann N Y Acad Sci. 1996, 784: 149-72. 10.1111/j.1749-6632.1996.tb16234.x.CrossRef Auricchio F, Migliaccio A, Castoria G, Di Domenico M, Bilancio A, Rotondi A: Protein tyrosine phosphorylation and estradiol action. Ann N Y Acad Sci. 1996, 784: 149-72. 10.1111/j.1749-6632.1996.tb16234.x.CrossRef
29.
go back to reference Migliaccio A, Piccolo D, Castoria G, et al: Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 1998, 17: 2008-18. 10.1093/emboj/17.7.2008.CrossRef Migliaccio A, Piccolo D, Castoria G, et al: Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 1998, 17: 2008-18. 10.1093/emboj/17.7.2008.CrossRef
Metadata
Title
Estrogen receptor α (ERα) mediates 17β-estradiol (E2)-activated expression of HBO1
Authors
Wen-zhong Wang
Hai-ou Liu
Yi-hong Wu
Yi Hong
Jun-wu Yang
Ye-heng Liu
Wei-bin Wu
Lei Zhou
Lin-lin Sun
Jie-jie Xu
Xiao-jing Yun
Jian-xin Gu
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-29-140

Other articles of this Issue 1/2010

Journal of Experimental & Clinical Cancer Research 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine